Abstract: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and X and Y, independently of one another, are a straightchain or branched alkylene bridge with 1 to 20 carbon atoms, preferably an alkylene bridge with 1 to 3 carbon atoms, which is unsubstituted or substituted by halogen, cyano or nitro. Furthermore, an essentially non-therapeutical process for deterring vermin is described, which is based on the usage of these compounds, as well as verminrepellent compositions containing these compounds as the active ingredient, and finally the use of these compounds for producing vermin-deterring compositions and their usage in deterring vermin from animals, humans and objects. New compounds within the scope of formula (I) are also described.

Abstract: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.

Abstract: The deodorized, polyether-modified polysiloxane composition not producing a substance giving off a foul odor, while being produced or stored, which results from hydrolysis, oxidation or the like of a by-product or unreacted material and temporarily stable, a method for producing the same, and a cosmetic containing the same, wherein a polyether-modified polysiloxane composition, synthesized by hydrosilylation in which a polyoxyalkylene having the carbon-carbon double bond at the terminal is reacted with an organohydrogen polysiloxane, is refined by treatment in the presence of a solid acid.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: A composition for application to exterior surfaces, such as trees, so as to prevent animal damage to the exterior surface, has asphalt and denatonium benzoate mixed together. The denatonium benzoate is 1% to 50% by weight of the total composition. The asphalt is between 50% and 60% of the total composition. Naphtha and dimethyl ether are further components of the total composition. The composition is sprayable onto the exterior surface.

Abstract: The present invention provides methods of using halogenated volatile compounds, e.g., halogenated ether, for treating a neurological disorder, e.g., Parkinson's disease.

Abstract: Inhaled anesthetics with otherwise desirable properties but which are too extensively degraded by passage through absorbents containing calcium hydroxide plus sodium hydroxide (such as soda lime) can be used as anesthetics by substituting absorbents containing calcium hydroxide but devoid of sodium hydroxide or containing minimal amounts of sodium hydroxide.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline.

Abstract: This invention relates to methods of inhibiting a Cav3 calcium channel in a cell using a C2-C10 alkyl alcohol, or mixtures thereof. This invention further relates to methods of treating a thalamocortical dysrhythmia disorder in a mammal and for treating a neurological disorder in a mammal associated with the thalamocortical dysrhythmia using a C2-C10 alkyl alcohol, a lipophilic molecule with a partition coefficient substantially similar to that of a C2-C10 alkyl alcohol, or mixtures thereof, or a pharmaceutical composition comprising the same.

Abstract: The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and/or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents.

Abstract: Drug delivery models, displays, and systems may be configured to provide a clinician with readily intuitive information about the effects of one or more drugs on a subject. Interactive features may be included to provide a subject-specific model of the expected or predicted effects of one or more drugs on the subject. Additionally, interactive features that effect drug delivery to the subject may also be included. Drug delivery models, displays, and systems may be used in teaching, in advance of treatment, during treatment, or following treatment.

Abstract: A smooth, dry-feeling, less-greasy, substantially-odorless, ecotoxicologically-safe, wax-based composition with a melting point above 25° C., comprising one or more wax components selected from dialkyl carbonates, dialkylene carbonates, and mixtures of two or more thereof; less than 10%, by weight, of water; and (c) optionally, one or more components selected from the group consisting of one or more wax or oil components selected from the group consisting of dialkyl ethers, dialkylene ethers, dicarboxylic acids, hydroxyfatty alcohols, and mixtures of two or more thereof, as well as one or more wax-like lipid components, other than those in previously listed, one or more other oil components, liquid at 20° C. and immiscible with water at 25° C.

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: A system and method for displaying a pharmacokinetics/pharmacodynamics drug model for a patient is provided. A monitor is arranged to detect a quantity of anesthetic agent provided to a patient by an anesthesia machine. A display is provided for displaying real-time pharmacokinetics data associated with the quantity of anesthetic agent provided to the patient. Safety control means are provided to initiate the display of real-time pharmacokinetics data for the anesthetic agent only when a predetermined threshold value for the anesthetic agent is detected by the monitor. Alternately, control means are adapted to terminate display of real-time pharmacokinetics data for the anesthetic agent when a predetermined threshold value for the anesthetic agent is detected by the monitor.

Abstract: An aqueous ophthalmic composition comprising a branched glycerol compound selected from the group consisting of a branched, glycerol monoalkyl ether, a branched, glycerol monoalkyl amine, a branched, glycerol monoalkyl sulfide, or any mixture thereof, present in a total amount of from 0.05 ppm to 1,000 ppm; a cationic antimicrobial component, and having an osmolality in a range from 200 mOsmol/kg to 400 mOsmol/kg. The presence of the branched glycerol compound enhances the biocidal efficacy of the aqueous ophthalmic composition containing one or more cationic antimicrobial components.

Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: A sustained release microcapsule comprises (a) an interfacially-polymerized polymer shell comprising at least one shell stabilizer; and (b) a fill composition comprising (1) at least one semiochemical and (2) at least one fill stabilizer.

Abstract: Polyacetals comprising a recurring units represented by a formula selected from the group consisting of formula (I) and (II): wherein A comprises at least one acetal group; B is selected from the group consisting of —CH—, —CH(CH3)—, CH2CH—, —CH2C(CH3)—, —CH(CH3)CH—, and —CHCH(CH3)CH(CH3)—; Z is selected from the group consisting of C(O)OR1, C(O)SR1, C(O)NR1R2, and VU; V is a linker group; U is selected from the group consisting of poly(ethyleneimine), poly(propyleneimine), poly(lysine), PAMAM dendrimer, octaamine dendrimer, hexadecaamine dendrimer, enhancer, and targeting receptor; R1 and R2 are each individually selected from the group consisting of hydrogen, C1 to C10 alkyl, and C6 to C10 aryl; D is a linkage selected from the group consisting of carboxylic amide, carboxylic ester, urea, and urethane; and G is selected from the group consisting of C4 to C20 alkyl, C6-C10 aryl, and —(OCH2CH2)n—, where n is in the range of 1 to about 250, are useful in nucleic acid delivery applications.

Abstract: A polymer comprising recurring units represented by formula (I): wherein X is selected from the group consisting of C(O)OR1, C(O)SR1, C(O)NR1R2, and VZ, where R1 and R2 are each individually selected from the group consisting of hydrogen, C1 to C10 alkyl, and C6 to C10 aryl, where V is a labile linker group, and where Z is selected from the group consisting of poly(ethyleneimine), poly(propyleneimine), poly(lysine), PAMAM dendrimer, octaamine dendrimer, and hexadecaamine dendrimer; and wherein Y is selected from the group consisting of —(CH2)2—, —(CH2)2—O—(CH2)2—, —(CH2)2—O—(CH2)2—, and —(CH2)3—NHC(O)—(CH2)6—C(O)NH—(CH2)3— is useful in nucleic acid delivery applications. Polyacetals of the formula (I) are preferably made by reacting appropriate diols and divinyl ethers. In preferred embodiments, complexes formed between polyacetals of the formula (I) and polynucleotides are useful as transfection reagents.

Abstract: Antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations which are more effective than prior art compositions without causing increased irritation to the skin of the average user. In certain embodiments, skin irritation may be minimized by low concentrations of antimicrobials and/or the presence of soothing compounds such as zinc. Preferred embodiments include combinations of octoxyglycerin, a quaternary compound, and at least one other antimicrobial agent. Without being bound to any particular theory, it is hypothesized that the unexpected antimicrobial effectiveness of combinations of octoxyglycerin may result from an enhancement of the permeability of microbes to antimicrobials caused by octoxyglycerin.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: Use of a composition which contains (a) one or more 1- or 2-(C3 to C24-alkyl)glycerol ethers and (b) one or more aromatic alcohols for the disinfection of the surface of an article at a temperature above 25° C.

Abstract: Use of a composition which contains 1-(2-ethylhexyl)-glycerol ether for the disinfection of the surface of an article at a temperature above 25° C.

Abstract: The present invention is directed, inter alia, to a method for delivering a compound into a cell comprising administering to the cell the compound to be delivered, an organic halide, and/or a carrier. Ultrasound may also be applied, if desired.

Abstract: Disclosed are methods of lowering plasma CRP levels, reducing systemic inflammation, and inhibiting proinflammatory cytokine induced CRP production by administering an effective amount of a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of the substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl or a pharmaceutical composition comprising a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl.

Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Abstract: A solution, in particular for hemodialysis or peritoneal dialysis that permits attaining a desired glucose concentration without affecting the concentrations of other components in the solution. The solution consists of at least three individual solutions that are combined and administered after heat sterilization. The first solution contains calcium ions, electrolyte salts and optionally glucose in a concentration of 0-1000 mM and is acidified to a pH of less than 4.0 with a physiologically tolerable acid. The second solution contains glucose in a concentration different from that of the first solution and the remaining components of the first solution in the same concentration. The third solution contains a buffer in the physiological range. Also provided is a method of preparing a solution according to the invention, where the desired mixing ratio of the separate solutions is automatically established by a dialysis machine or peritoneal dialysis cycler.

Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Abstract: The present invention provides a method for suppressing human activity in enclosed spaces. More particularly, the invention provides a method for the introduction of anesthesia into an enclosed space for the purpose of rendering occupants of the enclosed space unconscious.

Abstract: A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing one or more of polypropylene, polyethylene, and ionomeric resins. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.

Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Abstract: A method of and compositions for suppressing the growth of tumor cells in a patient are disclosed. In one embodiment, the method comprises treating the patient with an effective amount of an isoprenoid ether-linked compound, wherein the isoprenoid ether-linked compound comprises a first acyclic isoprenoid molecule linked via an ether linkage to a second molecule, wherein the second molecule can suppress tumor formation.

Abstract: An absorbent article, particularly a tampon having additives that reduce toxic shock syndrome toxin (TST-1) production is disclosed. The tampon has a combination of an effective amount of at least one oxygen inhibiting agent and an effective amount of at least one surface active agent applied to: the surface of the absorbent tampon material; the surfaces of the fibers comprising the tampon; to the tampon applicator; or any combination of the foregoing. The effective amounts of the oxygen inhibiting agent and the surface active agent are sufficient to reduce the toxin production at lease about 50%, but do not negatively affect the wearer's normal vaginal flora.

Abstract: An absorbent article having a bodyside liner includes a hydrophilic lotion formulation on the outer bodyfacing surface thereof. The hydrophilic lotion formulation comprises from about 10 to about 90 weight percent of a hydrophilic solvent, from about 5 to about 90 weight percent of a high molecular weight polyethylene glycol, and from about 0 to about 60 weight percent of a fatty alcohol. The hydrophilic lotion formulation has a reduced adverse effect on the absorbent and liquid uptake properties of the liner and the absorbent body when compared to conventional lipophilic or hydrophobic lotion formulations. The hydrophilic lotion formulation acts as a lubricant to reduce the abrasion of the skin caused by the liner and also transfers to the skin to provide improved skin health.

Abstract: The application of film-forming compositions to aquatic sites, especially aquatic breeding sites for control of surface-active aquatic breeding insects other than black flies, especially for immature mosquitos, has been found to be enhanced when different compounds than those suggested in the prior art are used. The compounds according to the present invention comprise film-forming chemicals which are biodegradable, nonionic, insoluble or partially soluble in water, and include C6, C7, C8, C9, C10, and C11 alcohol ethoxylates, propoxylates, and/or alkoxylates with an average of one (1) to five (5) moles of ethylene and/or propylene oxide per mole of alcohol, and mixtures thereof. The compositions may be applied directly as liquids or released into the aquatic environment from a carrier, such as a biodegradable, water-erodible, water-soluble or water-dispersible carrier.

Abstract: The present invention relates to methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension comprising administering a composition comprising an ether compound.

Abstract: A method and product for treating and preventing diarrhea and scours is provided. The method involves treating a subject who has diarrhea, or scours, or is at risk of getting diarrhea or scours with an aromatic compound of the invention. The products of the invention are a veterinary preparation of the aromatic compound of the invention and an anti-scours agent, and a pharmaceutical preparation of the aromatic compound of the invention and an anti-diarrheal agent.

Abstract: Compositions having broad effectiveness against bacterial and fungi, which comprise (a) an iodopropynylbutyl compound and (b) one or more formaldehyde donor compounds, the formaldehyde donor compounds being N-formals, O-formals and/or a combination thereof. The compositions are also stable and effective in the form of liquid concentrates. The present invention also relates to the use of such compositions in industrial products and to industrial products which comprise these compositions.

Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1)(R2)(R3)N→O  (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.

Abstract: The present invention relates to oral compositions and methods for inhibiting bone resoprtion in a mammal while counteracting the occurrence of potentially adverse gastrointestinal effects. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically-acceptable salt thereof and a pharmaceutically effective amount of an isoprenoid compound.

Abstract: A disinfecting composition which is bactericidal and effective to kill yeast includes (a) at least one a monocarboxylic acid of formula R—COOH, in which R a saturated or unsaturated, straight- or branched-chain alkyl radical comprising from 6 to 12 carbon atoms; (b) a strong inorganic acid; (c) at least one organic acid of formula R′CH2—CO2H, in which R′ is H or OH; (d) at least one anionic surfactant; (e) at least one solubilizing agent consisting of a compound of formula R″O(CH2CH2O)x—H, in which R″ represents a C2 to C6 alkyl radical, x represents an integer from 1 to 3; and (f) water.

Abstract: Compositions having broad effectiveness against bacteria and fungi, which comprise (a) an iodopropynylbutyl compound and (b) one or more formaldehyde donor compounds, the formaldehyde donor compounds being N-formals, O-formals and/or a combination thereof. The compositions are also stable and effective in the form of liquid concentrates. The present invention also relates to the use of such compositions in industrial products and to industrial products which comprise these compositions.

Abstract: A method of inhibiting or preventing the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of administering a compound selected from the group consisting of citracetal, citral dimethyl acetal, citral diethyl acetal, geranyl benzoate, geranyl tiglate, geranyl anthranilate, farnesyl benzoate, farnesyl anthranilate, farnesyl tiglate, farnesyl acetate and combinations thereof to a human tumor patient, wherein the amount is effective to reduce or inhibit tumor growth by at least 50%.

Abstract: An insecticidal and miticidal composition is provided which comprises at least one fatty acid ester selected from the group consisting of glycerin monooleate, glycerin monolinolate, glycerin monocaprylate, glycerin mono/dioleate, glycerin di/trioleate, glycerin mono/dilinolate, glycerin mono/diricinoleate, glycerin diacetomonolaurate, sorbitan laurate, sorbitan oleate, diglycerin laurate, diglycerin oleate, diglycerin monolaurate, diglycerin monooleate, tetraglycerin oleate, hexaglycerin laurate, decaglycerin laurate, propylene glycol monolaurate, and propylene glycol monooleate; and a nonionic surfactant. The insecticidal and miticidal composition does not have phytotoxicity but has satisfactory long lasting effects even if it is used in a lower concentration.

Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Abstract: A &bgr;,&ggr;-dihydropolyprenyl alcohol derivative having the formula: wherein n is an integer of 5 to 7 and R is hydrogen, a lower alkyl group or an aliphatic or aromatic acyl group, is new and useful as a prophylactic therapeutic agent for human and animal immuno-deficiency deseases and phylactic agent against human and animal infectious deseases. Another disclosed polyprenyl compound is also useful as the same agent.

Abstract: Disorders of the skin and mucous membranes that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor &agr;, and oxysterol activators of the LXR&agr; receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.